Skip to content

PTC518 PIVOT-HD Study Achieves Primary Endpoint

May 5, 2025 PDF Version – Study met primary endpoint with dose-dependent blood HTT protein lowering at Week 12 – – Favorable dose-dependent trends across clinical scales in Stage 2 […]

Update on the Phase II GENERATION HD2 study

Roche has announced the continuation of the GENERATION HD2 Phase II clinical trial evaluating tominersen in individuals with early signs of Huntington’s disease. Following an interim analysis by an independent committee, no […]

EHA Conference 2025

We are excited to announce that the European Huntington Association will be organising its 5th Biannual Conference in Bucharest, Romania, from September 25th-28th, 2025. “Shaping our Future Together, We are the Change!” encapsulates the spirit […]

A Look Back at the HDYO Congress 2025

The HDYO Congress 2025 brought together young people, families, researchers, and professionals from around the world for an unforgettable event dedicated to the Huntington’s Disease community. Over three inspiring days, […]

en_USEnglish